Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Immunology · Immunodeficiency 99

Long-Term Monitoring and Living with IMD99

At a Glance

Living with Immunodeficiency 99 (IMD99) means following a personalized monitoring plan for blood counts and antibody levels, watching kidney, liver, and lung health, and preventing infections. Vaccines, fatigue, sleep, anxiety, and social well-being should be discussed with the care team.

Living with Immunodeficiency 99 (IMD99) is not just about treating an illness; it is about managing a lifelong routine of observation. Because this condition involves both an underactive and an overactive immune system, your “wellness” depends on regular monitoring to catch shifts in your blood counts or antibody levels before they cause symptoms [1][2].

Your Surveillance Schedule

While your schedule will be personalized by your specialists, patients with complex immune dysregulation typically follow a “tiered” monitoring plan. This ensures that every organ system potentially affected by IMD99 is checked regularly [3][2]. These intervals are examples only; active cytopenia or immunosuppressant use may require drug-specific and much more frequent CBC, renal, liver, lipid, or other monitoring.

Routine Laboratory Checks

  • Complete Blood Count (CBC): When you are stable, this is often checked every 3 to 6 months. If you are currently experiencing low platelets or anemia, or if you have just changed your immunosuppressant dose, it may be checked weekly or bi-weekly [4][5].
  • IgG Trough Levels: These are measured just before your next dose of immunoglobulin. If you use SCIG (under the skin), this may be checked less frequently once a steady level is reached, as SCIG does not produce the same peak-and-trough pattern as IVIG. If you use IVIG, it is often checked every few months to ensure your dose is high enough to prevent infections [6][7].
  • Organ Screening: At least once a year, your doctors may check your liver and kidney function and perform a Pulmonary Function Test (PFT) to monitor your lung health [3][8].

Specialist Visits

  • Immunology and Hematology: Even when you feel well, you should have a “comprehensive review” at least once or twice a year. During these visits, your doctors will feel for an enlarged spleen or lymph nodes and review your infection history [2][3].

Daily Management and Infection Prevention

Living with an immunodeficiency requires a “proactive” approach to daily life. The goal is to minimize risk without living in total isolation.

  • Pharmacological Protection: Depending on your overall T-cell defect, prolonged corticosteroid exposure, combinations of immunosuppressants, prior opportunistic infection, and specialist guidance, your doctor may prescribe prophylactic antibiotics (such as trimethoprim-sulfamethoxazole) to prevent specific types of pneumonia [9].
  • Vaccination Strategy: Most non-live vaccines, like the flu shot or recombinant zoster vaccine (Shingrix), are usually safe, though they may be less effective or require timing around IVIG or anti-CD20 therapy [10][11]. Live vaccines (like MMR or live zoster vaccines) are generally avoided in patients with combined immunodeficiency unless specifically cleared by your immunologist, depending on the degree of T-cell dysfunction [10]. Review both your own and household members’ vaccines with your immunologist.
  • Home Adjustments: Simple habits, such as high-quality handwashing and avoiding close contact with people who have active infections, remain the most effective daily protections [12].
  • Life Planning: Family planning, pregnancy, genetic counseling, travel planning, and access to an immunology center or rare-disease registry are particularly relevant topics to discuss for heritable IEIs.

The “Unseen” Symptoms: Fatigue and Mental Health

For many patients with IMD99, the most difficult symptoms aren’t the infections, but the chronic fatigue and the psychological weight of the diagnosis [13].

  • Chronic Fatigue: This is a very common issue in immunodeficiency [14]. It is often not related to how “active” your disease is. Fatigue in IMD99 can be worsened by poor sleep quality or the underlying inflammation in your body [15][13]. However, do not assume new fatigue is just part of the condition. It can reflect anemia, infection, inflammation, sleep problems, medication effects, endocrine disease, or other conditions. New or worsening fatigue requires evaluation.
  • Psychological Toll: Constant monitoring can lead to “diagnostic anxiety.” Research shows that many patients with rare immunodeficiencies experience elevated levels of stress and anxiety related to self-isolation and the unpredictability of their health [16][12].
  • Empowerment through Activity: Staying engaged in work, school, or social activities—with the appropriate safety precautions—has been shown to improve self-esteem and overall well-being for people with immune disorders [17][18].

Finding a balance between being “careful” and “living” is a skill that takes time to develop. By working closely with a multidisciplinary team and focusing on your total well-being—including sleep and mental health—you can maintain a high quality of life while managing IMD99 [19][20].

Common questions in this guide

How often should I have CBC and IgG monitoring for IMD99?
The schedule is individualized. When IMD99 is stable, a complete blood count (CBC) is often checked every 3 to 6 months, but active low platelets or anemia, or a recent immunosuppressant change, may require weekly or every-other-week testing. An IgG level is usually checked just before an immunoglobulin dose; treatment through a vein (IVIG) may require checks every few months, while treatment under the skin (SCIG) may need less frequent checks after levels are stable.
What other health checks are important for someone living with IMD99?
Care may include at least yearly kidney and liver blood tests and a pulmonary function test to check breathing and lung health. Immunology and blood specialists are often seen once or twice a year, even when you feel well, to review infections and check for an enlarged spleen or lymph nodes. The schedule may be more frequent when blood counts are changing or medicines require closer monitoring.
Which vaccines are recommended or avoided with IMD99?
Non-live vaccines, such as the flu shot and recombinant shingles vaccine, are usually considered safe but may work less well or need timing around IVIG or anti-CD20 treatment. Live vaccines, such as MMR or live shingles vaccine, are generally avoided in combined immunodeficiency unless an immunologist specifically approves them. Ask about both your own and your household members' vaccines.
Can IMD99 cause fatigue or brain fog?
Chronic fatigue can occur with immunodeficiency, but new or worsening fatigue should not automatically be blamed on IMD99. A clinician may look for anemia, infection, inflammation, poor sleep, medication effects, hormone-related problems, or another condition. Tracking sleep, fatigue, and brain fog can help guide that evaluation.
When might prophylactic antibiotics be used with IMD99?
An immunologist may consider preventive antibiotics when infection risk is increased by a weakness in T-cell immunity, prolonged steroid use, combinations of immune-suppressing medicines, or a past opportunistic infection. The decision depends on your history and current treatment, so do not start or stop an antibiotic without specialist guidance.
How can I protect my health and quality of life while living with IMD99?
Regular handwashing, avoiding close contact with people who have active infections, and following your personalized vaccine and medicine plan can reduce infection risk. Staying involved in work, school, exercise, and social activities with appropriate precautions may support well-being, while sleep, anxiety, and fatigue should be discussed with your care team. Family planning, travel, and genetic counseling may also deserve advance planning.

Get notified when new evidence is published on immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.

    Westermann-Clark E, Meehan CA, Meyer AK, et al.

    Frontiers in immunology 2021; (12()):649182 doi:10.3389/fimmu.2021.649182.

    PMID: 33968040
  2. 2

    Multidisciplinary Delphi consensus on malignancy screening in patients with common variable immunodeficiency.

    Cabanero-Navalon MD, de Andrés-Martín A, Gil AA, et al.

    Frontiers in immunology 2026; (17()):1897051 doi:10.3389/fimmu.2026.1897051.

    PMID: 42676356
  3. 3

    State-of-the-art diagnostic evaluation of common variable immunodeficiency.

    Lee TK, Gereige JD, Maglione PJ

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (127(1)):19-27 doi:10.1016/j.anai.2021.03.005.

    PMID: 33716149
  4. 4

    Peripheral-blood cytopenia, an early indicator of inborn errors of immunity.

    Cornelissen HM, Musekwa EM, Glashoff RH, et al.

    British journal of haematology 2022; (198(5)):875-886 doi:10.1111/bjh.18337.

    PMID: 35791731
  5. 5

    Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.

    Athni TS, Barmettler S

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):699-712 doi:10.1016/j.anai.2023.01.018.

    PMID: 36706910
  6. 6

    Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.

    Pecoraro A, Ricci S, Vultaggio A, et al.

    Clinical drug investigation 2020; (40(3)):279-286 doi:10.1007/s40261-020-00885-8.

    PMID: 32036588
  7. 7

    Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: A 2-year real-life experience.

    Vivarelli E, Matucci A, Bormioli S, et al.

    Clinical and experimental immunology 2021; (205(3)):346-353 doi:10.1111/cei.13629.

    PMID: 34061980
  8. 8

    Clinical manifestations and approach to the management of patients with common variable immunodeficiency and liver disease.

    Daza-Cajigal V, Segura-Guerrero M, López-Cueto M, et al.

    Frontiers in immunology 2023; (14()):1197361 doi:10.3389/fimmu.2023.1197361.

    PMID: 37342345
  9. 9

    [Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency].

    Hanitsch LG

    Der Internist 2022; (63(5)):484-492 doi:10.1007/s00108-022-01326-8.

    PMID: 35412057
  10. 10

    Vaccination in Primary Immunodeficiency Disorders.

    Sobh A, Bonilla FA

    The journal of allergy and clinical immunology. In practice 2016; (4(6)):1066-1075 doi:10.1016/j.jaip.2016.09.012.

    PMID: 27836056
  11. 11

    The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.

    Robbins A, Bahuaud M, Hentzien M, et al.

    Frontiers in immunology 2021; (12()):697128 doi:10.3389/fimmu.2021.697128.

    PMID: 34290713
  12. 12

    Perceived control is significantly associated with psychological adaptation in individuals with known or suspected inborn errors of immunity.

    Setzer M, Yan J, Erby L, Similuk M

    Journal of community genetics 2023; (14(6)):639-647 doi:10.1007/s12687-023-00670-y.

    PMID: 37709977
  13. 13

    Severe Fatigue Is Common Among Pediatric Patients with Primary Immunodeficiency and Is Not Related to Disease Activity.

    Nijhof LN, van Brussel M, Pots EM, et al.

    Journal of clinical immunology 2021; (41(6)):1198-1207 doi:10.1007/s10875-021-01013-7.

    PMID: 33728554
  14. 14

    Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry.

    Hajjar J, Guffey D, Minard CG, Orange JS

    Journal of clinical immunology 2017; (37(2)):153-165 doi:10.1007/s10875-016-0367-1.

    PMID: 28124237
  15. 15

    Assessment of Sleep Disorders in Patients with CVID.

    Punj M, Neshat SS, Mateus AYL, et al.

    Journal of clinical immunology 2024; (44(5)):109 doi:10.1007/s10875-024-01711-y.

    PMID: 38676767
  16. 16

    Frequency of depression and anxiety in patients with inborn errors of immunity: a cross-sectional study.

    Wolff LJ, Witte T, Kahl KG, et al.

    BMC psychiatry 2026; (26(1)).

    PMID: 42745244
  17. 17

    Vulnerability beyond infection: Effects of peer victimization on quality of life and psychosocial well-being in inborn errors of immunity.

    Meric Z, Durcan G, Coban ZB, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2026; (37(3)):e70318 doi:10.1111/pai.70318.

    PMID: 41800593
  18. 18

    Patient-reported outcomes in patients with primary immunodeficiency diseases in Japan: baseline results from a prospective observational study.

    Kanegane H, Ishimura M, Kawai T, et al.

    Frontiers in immunology 2023; (14()):1244250 doi:10.3389/fimmu.2023.1244250.

    PMID: 37828988
  19. 19

    Shared Decision-Making and Health-Related Quality of Life in the Diagnosis and Management of Patients With Inborn Errors of Immunity.

    Lawrence MG, Kim VHD, Orange JS, Scherzer R

    The journal of allergy and clinical immunology. In practice 2026; doi:10.1016/j.jaip.2026.07.010.

    PMID: 42447994
  20. 20

    Perceived Sleep Quality in Individuals with Inborn Errors of Immunity.

    Sowers KL, Sawaged A, Bowen B

    Journal of clinical immunology 2023; (43(6)):1221-1228 doi:10.1007/s10875-023-01474-y.

    PMID: 36959490

This page is for informational purposes only and does not constitute medical advice. Your immunologist and hematologist should personalize your tests, vaccines, medicines, and activity guidance.